The myelodysplastic syndromes

Bibliography

• LIST AF, VARDIMAN J, ISSA JP, DEWITTE TM: Myelodysplastic syndromes. Hematology (Am. Soc. Hematol. Educ. Program) (2004) 2004:297-317.
   Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol. (1999) 10(12):1419-1432.
   PubMed Web of Science ®Google Scholar
• AUL C, GATTERMANN N, SCHNEIDER W: Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br. J. Haematol. (1992) 82(2):358-367.
   PubMed Web of Science ®Google Scholar
• PAUL B, REID MM, DAVISON EV, ABELA M, HAMILTON PJ: Familial myelodysplasia: progressive disease associated with emergency of monosomy 7. Br. J. Haematol. (1987) 65(3):321-323.
   PubMed Web of Science ®Google Scholar
• PASQUALETTI P, CASALE R, COLANTONIO D, COLLACCIANI A: Occupational risk for hematological malignancies. Am. J. Hematol. (1991) 38(2):147-149.
   PubMed Web of Science ®Google Scholar
• KARP JE, SMITH MA: The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin. Oncol. (1997) 24(1):103-113.
   PubMed Web of Science ®Google Scholar
• BELLAMY WT, RICHTER L, SIRJANI D et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood (2001) 97(5):1427-1434.
   PubMed Web of Science ®Google Scholar
• SCHIPPERUS M, SONNEVELD P, LINDEMANS J et al.: The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. Leukemia (1990) 4(4):267-272.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO K, HIRANO N, TOYOSHIMA H et al.: Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood (1993) 81(11):3022-3026.
   PubMed Web of Science ®Google Scholar
• HAASE D, STEIDL C, SCHANZ J et al.: Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS. Blood (2005) 106:232a.
   Web of Science ®Google Scholar
• GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89(6):2079-2088.
   PubMed Web of Science ®Google Scholar
• BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. (1982) 51(2):189-199.
   PubMed Web of Science ®Google Scholar
• VARDIMAN JW, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100(7):2292-2302.
   PubMed Web of Science ®Google Scholar
• MALCOVATI L, GERMING U, KUENDGEN A et al.: A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood (2005) 106:232a.
   Google Scholar
• CHESON BD, GREENBERG PL, BENNETT JM et al.: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 108(2):419-425.
   PubMed Web of Science ®Google Scholar
• HELLSTROM-LINDBERG E, NEGRIN R, STEIN R et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. (1997) 99(2):344-351.
   PubMed Web of Science ®Google Scholar
• HELLSTROM-LINDBERG E, GULBRANDSEN N, LINDBERG G et al.: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. (2003) 120(6):1037-1046.
   PubMed Web of Science ®Google Scholar
• SEKERES M, FU A, MACIEJEWSKI J, GOLSHAYAN A, KALAYCIO M, KATTAN M: A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Blood (2005) 106:711a.
   Google Scholar
• CORRAL LG, KAPLAN G: Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. (1999) 58(Suppl. 1):I107-113.
   PubMed Web of Science ®Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98(1):210-216.
   PubMed Web of Science ®Google Scholar
• GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31(2-3):213-221.
   PubMed Web of Science ®Google Scholar
• PARMAN T, WILEY MJ, WELLS PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. (1999) 5(5):582-585.
   PubMed Web of Science ®Google Scholar
• RAZA A, MEYER P, DUTT D et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 98(4):958-965.
   PubMed Web of Science ®Google Scholar
• CHESON BD, BENNETT JM, KANTARJIAN H et al.: Myelodysplastic syndromes standardized response criteria: further definition. Blood (2001) 98(6):1985.
   PubMed Web of Science ®Google Scholar
• MUSTO P, FALCONE A, SANPAOLO G, BISCEGLIA M, MATERA R, CARELLA AM: Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica (2002) 87(8):884-886.
   PubMed Web of Science ®Google Scholar
• STRUPP C, GERMING U, AIVADO M, MISGELD E, HAAS R, GATTERMANN N: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia (2002) 16(1):1-6.
   PubMed Web of Science ®Google Scholar
• MORENA-ASPITIA A, GEYER S, LI C-Y et al.: N998B: multicenter Phase II trial of thalidomide (thal) in adult patients with myelodysplastic syndromes (MDS). Blood (2002) 100:96a.
   PubMed Web of Science ®Google Scholar
• LIST A, TATE W, GLINSMANN-GIBSON B: The immunomodulatory thalidomide analog, CC-5013, inhibits tropic response in VEGF in AML cells by abolishing cytokine-induced PI3/Akt activation. Blood (2002) 100:139a.
   Google Scholar
• LIST A, KURTIN S, ROE D et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. (2005) 352(6):549-557.
   PubMed Web of Science ®Google Scholar
• LIST A, DEWALD G, BENNETT J et al.: Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study. J. Clin. Oncol. (Proc. Am. Soc. Clin. Oncol.) (2005) 23:2s.
   Google Scholar
• SCHILLER GJ, SLACK J, HAINSWORTH JD et al.: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J. Clin. Oncol. (2006) 24(16):2456-2464.
   PubMed Web of Science ®Google Scholar
• VEY N, BOSLY A, GUERCI A et al.: Arsenic trioxide in patients with myelodysplastic syndromes: a Phase II multicenter study. J. Clin. Oncol. (2006) 24(16):2465-2471.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR: Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist (2001) 6(Suppl. 5):8-14.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR, DEMAKOS EP, PETERSON BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. (2002) 20(10):2429-2440.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. (2006) 24(24):3895-3903.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, ISSA JP, ROSENFELD CS et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer (2006) 106(8):1794-1803.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, OKI Y, GARCIA-MANERO G et al.: Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) (In Press).
   Google Scholar
• ESTEY E: Reducing mortality associated with immediate treatment complications of adult leukemias. Semin. Hematol. (2001) 38(4 Suppl. 10):32-37.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, BERAN M, CORTES J et al.: Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer (2006) 106(5):1099-1109.
   PubMed Web of Science ®Google Scholar
• HALLEMEIER CL, GIRGIS MD, BLUM WG et al.: Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol. Blood Marrow Transplant. (2006) 12(7):749-757.
   Google Scholar
• ALYEA EP, KIM HT, HO V et al.: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood (2005) 105(4):1810-1814.
   PubMed Web of Science ®Google Scholar
• ANDERSON JE, APPELBAUM FR, FISHER LD et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood (1993) 82(2):677-681.
   PubMed Web of Science ®Google Scholar
• SIERRA J, RADICH J, HANSEN JA et al.: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (1997) 90(4):1410-1414.
   PubMed Web of Science ®Google Scholar
• RUNDE V, DE WITTE T, ARNOLD R et al.: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. (1998) 21(3):255-261.
   PubMed Web of Science ®Google Scholar
• SUTTON L, CHASTANG C, RIBAUD P et al.: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood (1996) 88(1):358-365.
   PubMed Web of Science ®Google Scholar
• CUTLER CS, LEE SJ, GREENBERG P et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood (2004) 104(2):579-585.
   PubMed Web of Science ®Google Scholar
• WANG B, NICHOL JL, SULLIVAN JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. (2004) 76(6):628-638.
   PubMed Web of Science ®Google Scholar
• SALITURO FG, GERMANN UA, WILSON KP, BEMIS GW, FOX T, SU MS: Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. (1999) 6(9):807-823.
   Web of Science ®Google Scholar
• WARNECKE C, ZABOROWSKA Z, KURRECK J et al.: Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. (2004) 18(12):1462-1464.
   PubMed Web of Science ®Google Scholar
• KUENDGEN A, KNIPP S, FOX F et al.: Results of a Phase II study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. (2005) 84(Suppl. 13):61-66.
   PubMed Web of Science ®Google Scholar